Excellamol has developed a precision therapeutics delivery technology, Self-Depot™ OncoPDC, engineered to achieve sustained local retention, prolonged tumor exposure, and minimal systemic leakage in difficult-to-penetrate solid tumors.

Excellamol has received five U.S. FDA Orphan Drug Designations and successfully completed FDA regulatory interactions supporting IND-enabling development and first-in-human clinical planning.

The company is currently advancing GLP toxicology, pharmacokinetic, and CMC activities in support of the clinical development of novel therapies for malignant glioma and pancreatic cancer, both of which are hard-to-treat cancers associated with high mortality.